Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Major depressive disorder

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

Biogen appoints Jeff Capello as executive VP and CFO

He will lead the company's business and finance planning functions

Biogen Idec building

Biogen says trial extension data keep Alzheimer’s drug on track

Releases updated results from the PRIME trial of anti-amyloid drug aducanumab

- PMLiVE

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

- PMLiVE

Biogen develops quantum computing-based app to speed drug discovery

Collaborates with Accenture and 1QBit in neurological diseases

Biogen Idec building

Biogen wins European spinal muscular atrophy first

Spinraza wins accelerated approval to treat patients with the most common form of SMA

- PMLiVE

Biogen spin-out makes first acquisition

Bioverativ attains rare disease group True North

- PMLiVE

Otsuka refiles ‘digital’ medicine for mental illness

Soluble sensor tracks drug ingestion and shares information with HCPs

Biogen Idec building

Biogen hands out $120m upfront for Remedy stroke drug

Cirara vying to be first new treatment since the 1990s

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links